Global Clinical Trials Market Segmentation Analysis Report 2021-2026 | Global Clinical Trials Industry Analysis on Size, Share, Growth, Trends, Demand, Competitive Analysis, and Forecast Report 2021-2026

Published: September 2020  |  Report ID:1011  | Pages: 150

Global Clinical Trials Market Research Insights:

Global Clinical Trials Market value was at USD 18.04 billion in 2020 and, it is projected to reach USD 26.8 Billion by the end of 2026, and the market growth which is expected grow at a CAGR of 7.85% from 2020 to 2026.

Global Clinical Trials (GCT) means any clinical trial which is conducted as a part of Multinational Clinical Development for design and development for approval of any new drug. Clinical Trials is a systematic study of any new drugs as a human resource to generate data for discovering and/or verifying the clinical, pharmacological which includes pharmacodynamics and pharmacokinetics, and adverse effects with the objectives of determining safety and efficiency of a new drug.

Clinical developments teams are under high pressure, such as financial stakeholders, who are ready to expect a return from their investment; pressure from regulators, who are closely scrutinizing the biopharma industry as it explores new therapeutic platforms; mostly they get high pressure from patients and families, who are waiting for much-needed cures and life-enhancing treatments.

Global Clinical Trials Market: Overview:

Increasing the need for personalized medicines and orphan drugs, and demand for advanced technologies.

In the pharmaceutical sectors, the demand for CROs is increasing for conducting Clinical Trails due to the adoption of advanced technologies in clinical trials. Digitalization in biomedical research is also paving the highest role in the development of market growth. The market growth is also driven by the emergency of the global pandemic for coronavirus. The COVID-19 is impacting lives, communities, businesses, and industries around the world. However, to overcome this pandemic situation, researchers are rapidly trying to develop innovative therapeutics and vaccines against COVID-19, which is supporting by clinical trials market growth.

Clinical Trials Market: Phases insights

Clinical trials are main to promote the efficacy and safety of a new developed products which involved like drugs, novel vaccines, dietary supplements, and medical devices. In clinical Trials process there are four types of Phases or clinical Phases, called, Phase I, II, III and IV. A clinical trial should happen only post to receiving approval from the health authority/ethics committee on human trials.

Clinical trial information is major for drug approval, as well as for it to be present in the marketplace. These clinical trials are performed by three phases (I, II, and III), which is include various factors to complete the clinical process. This clinical trials process is so expensive, times consuming, and also it requires expertise at all stages.

Listing of Clinical Trial Registries:

In 2004, a Medical Journal Editors announced a policy, that as a condition of publications and clinical trials are required to be listed in a public registry. Some research funding agencies are now encouraging or requiring the registrations and the results of reporting clinical trials as they fund.

The World Health Organization (WHO) includes the following 20 elements in a clinical trials registry.

  1. Primary Registry and Trail identifying Number
  2. Date of Registration in Primary Registry
  3. Secondary Identifying Numbers
  4. Sources(s) of Monetary of Material Support
  5. Primary Sponsor(s)
  6. Secondary Sponsor(s)
  7. Contact for public Queries
  8. Public title
  9. Scientific title
  10. Contact for Scientific Queries
  11. Countries of Recruitment
  12. Intervention(s)
  13. Study type
  14. Key inclusion and exclusion criteria
  15. Health Condition(s) or Problem(s) Studied
  16. Date of the first environment
  17. Recruitment status
  18. Target Sample Size
  19. Primary Outcome(s)
  20. Key Secondary Outcome(s)

Research Analysis and Report Coverage:

  • Company Share
  • Revenue Forecast
  • Competitive Landscape
  • Growth Factors
  • Market Trends

Our research study is not restricted to the global level only, we also covered our research study by country in the Global Rodenticides market report are Canada, United States, Brazil, Mexico, Colombia, Czech Republic, Denmark, United kingdom, Argentina, Germany, Egypt, Finland, France, Ireland, Israel, Italy, Turkey, United Arab Emirates, Venezuela, Vietnam, Australia, Austria, Belgium,  Chile, China, Hong Kong, India, Indonesia, Japan, Malaysia, Netherlands, New Zealand, Nigeria, Norway, Peru, Philippines, Poland, Portugal, Romania, Russia, Saudi Arabia, Singapore, South Africa, South Korea, Spain, Sweden, Switzerland, and Thailand.

Regional and Country Analysis:

North America Share in Global Market:

Note* North America region is projected to remain its domination over the forecast period.

Asia Pacific region is projected to grow at the fastest CAGR of 6.1% from the forecast period remaining to the increasing accessibility of large patient pool facilitating easy recruitment of candidates. Asia region is one of the speedy growing global clinical trials market. The Asian countries taking lead in clinical trials market are India, China, Singapore, and South Korea.

North America is having the countries like U.S. and Canada, these countries have reported together to have the largest number of clinical trials conducted globally.

Coming to Europe region, Germany bonces the largest number of clinical trials. The German country was reported to have conducted 734 clinical trials for 2010 in Western Europe.

In Eastern Europe, Poland is accounted for the largest number of clinical trials, with total number of 263 clinical trials for 2010.

Global Clinical Trials Market Segmentation:

Segment 1: By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Phase III is the Largest Segment under these four Phases which is analyzed to Grow during the Forecast Period. Phase III is one of the most important and critical phases considering the success of the new intervention, as well as its importance in clinical practice.

In the year 2019, the Phase III segment dominated the global clinical trials market with a share of 53.0%. Phase III trials are the most expensive ones and involve huge subjects. Whereas Phase III requires a higher number of patients and often a longer treatment period.

In terms of market share accounting, the Phase II segment will follow Phase III for 19.8% in 2019. Phase II is the second most expensive stage after Phase III. This study includes 2 parts. The first part involves exploring a range of doses along with efficiency studies, and the second part includes the finalizing the dose. Phase II plays a crucial role, mainly in oncology-related studies. There are various therapeutic vaccines currently in Phase II for the treatment of coronavirus.

Phase I clinical trials evaluate the best way to administer a drug and its side effects.  If he or she is responding to the therapy, and if there are no severe side effects to the patient then doses are going to increase. Phase IV monitors long term effects and effectiveness.

Segment 2: By Study Design:

  • Interventional
  • Observational
  • Expanded Access

Segment 3: By Indication:

  • Autoimmune/Inflammation
  • Pain management
  • Cardiovascular
  • CNS condition
  • Oncology
  • Diabetes
  • Obesity
  • Others

Competitive Analysis:

The Major Important companies leading the global clinical trials industry listed in this report below: Omnicare, Chiltern, PPD, Parexel, Kendle International Inc, Quintiles, ICON Plc and Charles River

Other than the important Prominent Key Players covered in this report are:

  • Wuxi AppTec
  • PRA Health Sciences
  • SGS SA
  • Syneos Health
  • Eli Lilly and Company
  • Novo Nordisk A/S
  • Pfizer
  • Clinipace

According to our research study the major developments have occurred in Global Clinical Trials Market:

S.No Year Recent Development/Product Launches
1 In January 2020 Wuxi AppTec announced offering a fully integrated adeno-associated virus Vector Suspension Platform.

Ø  This is to speed up the cell and gene therapy development

Ø  Manufacturing and launch, thus, expanding its service capabilities.

2 In June 2016 Quintiles is the most significant research organization. It has launched a Continuous Glucose Monitoring Device, which is very helpful to record a person’s glucose levels throughout the day
3 In august 2017 LabCorp’s, it is a Lifesciences leading compnay.

Ø  Acquired Children with a transaction of approximately USD 1.2 billion.

4 In April 2018 ICON PLC., it is a company of global biopharmaceutical.

Ø  It has announced that it recently agreed with the Intel Pharma Analytics platform in clinical trials

5 In June 2018 Another case happened, Acurian & Synexus, a part of PPD, it is launched SynexusPlus.
6 In October 2018 Parexel announced to  launch new wearable, mobile technology for clinical trials
7 In October 2019 ICON acquired Symphony Clinical Research to enhance the ability in offering customers hybrid trial solutions and site support services
8 In February 2018 PPD and Acurian have introduced an innovative clinical trial patient concierge service that provides personalized patient support and improves customer retention

Report Coverage:

  • Revenue Forecast
  • Company Share
  • Competitive Landscape
  • Growth Factors
  • Market Trends
  1. Preface

1.1 Market Definition and Scope

1.2 Base Currency, Base Year and Forecast Periods

1.3 Key Research Objectives

1.4 Research Highlights

  1. General Study Assumptions
  2. Research Methodology

3.1 Introduction

3.2 Secondary Research

3.3 Primary Research

3.4 Analysis Design

3.5 Study Timeline

  1. Market Dynamics

4.1 Drivers

4.2 Restraints

4.3 Opportunities

4.4 Market Trends

  1. Supply Chain Analysis
  2. Company Strategy Analysis

6.1 Merger and Acquisition Analysis

6.2 Agreements, Collaborations and Joint Ventures

6.3 Regional Presence

6.4 New Product Launches

  1. Market Outlook

7.1 Technological Advancement

7.2 Pricing Analysis

7.3 Epidemiology

7.4 Product Landscape Analysis (Brand Tracking Analysis & Pipeline Analysis)

  1. Market Segmentation

8.1 Overview

8.2 Global Clinical Trials Market, By Phase, forecast year 2021-2026

8.2.1 Phase I

8.2.2 Phase II

8.2.3 Phase III

8.2.4 Phase IV

8.2.5 Market Size Estimations & Forecasts (2021-2026)

8.3.6 Y-o-Y Growth Analysis

8.3.7 Market Investment Opportunities Analysis

8.3 Global Clinical Trials Market, By Study Design, forecast year 2021-2026

8.3.1 Interventional

8.3.2 Observational

8.3.2 Expanded Access

8.3.3 Market Size Estimations & Forecasts (2021-2026)

8.3.4 Y-o-Y Growth Analysis

8.3.5 Market Investment Opportunities Analysis

8.4 Global Clinical Trials Market, By Indication, forecast year 2021-2026

8.4.1 Autoimmune/Inflammation

8.4.2 Pain management

8.4.3 Cardiovascular

8.4.4 CNS condition

8.4.5 Oncology

8.4.6 Diabetes

8.4.7 Obesity

8.4.8 Others

8.4.9 Market Size Estimations & Forecasts (2021-2026)

8.4.10 Y-o-Y Growth Analysis

8.4.11 Market Investment Opportunities Analysis

  1. Global Market Regional and Country Analysis, Forecast 2021-2026

9.1 Overview

9.2 Regional Trends

9.3 Impact Analysis

9.4 Key Findings

9.5 Global Clinical Trials Market,  by Region, 2021-2026

9.5.1 By Phase

9.5.2 By Sudy Design

9.5.3 By Indication

  1. Competitive Landscape Analysis

10.1 Market Player

10.1.1 Company Revenue

10.1.2 Business unit

10.1.3 Product Mapping

10.1.4 Geographical Locations

10.2 Company Share Analysis

  1. Strategic Analysis

11.1 PESTLE analysis

11.2 Porter’s Five analysis

11.2.1 Bargaining Power of Suppliers

11.2.2 Bargaining Power of Consumers

11.2.3 Threat of New Entrants

11.2.4 Threat of Substitute Products and Services

11.2.5 Competitive Rivalry within the Industry

  1. Company Profiles

12.1 Omnicare

12.1.1 Overview

12.1.2 Product Portfolio

12.1.3 Financial Details

12.1.4 SWOT Analysis

12.1.5 Market Strategies

12.2 Chiltern

12.3 PPD

12.4 Parexel

12.5 Kendle International Inc

12.6 Quintiles

12.7 ICON Plc

12.8 Charles River

  1. Market Guidance
  2. Appendix